Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D’Haens